Eli Lilly will submit orforglipron to be part of FDA’s new national priority voucher program, according to a new report. 1 ...

The GCC is becoming a strategic anchor for global venture capital, with Riyadh emerging as a key fundraising hub. Sovereign ...

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F.

The US Health Resources and Services Administration (HRSA) revealed the initial nine drugs to be included in the 340B rebate model. The decision comes after pharma companies filed suit in regard to ...

AbbVie revealed it has raised its annual profit forecast for 2025 after sales of its newest immunology drugs Skyrizi and Rinvoq strengthened the company’s Q3 sales number, exceeding expectations set ...

See how leading teams are achieving measurable impact in just 90 days—without adding validation debt or manual, swivel-chair workflows. Purpose-built, inspection-ready platforms now outpace custom ...

With Most Favored Nation (MFN) and the emergence of the direct-to-consumer (DTC) model and potential tariffs, traditional roles of payers, pharmacy benefit managers, manufacturers, and 340B hospitals ...